Time is money in biotech game - patents run out, competitors launch new products. But this arrogant management don’t seem to be in any hurry - just take home big share package as long as the good times last. too bad for investors.
if can’t recruit to study then haven’t got the right or enough clinicians or drug not compelling enough. bad sign. if keep argue over and over with drug regulator then poor advisors and head of regulatory should go .
if spend 20 years do R&D and not close to cash flow positive then not capble management. Just good at sell promises hope and dreams. failed (Lloyds, condoms, BV etc ) and non existent (viraleze, eg india) deals mounting up in a pile behind JF. I doubt the Vietnam deal has much margin is desperate attempt to save face at SPL. Quarterly will tell us more.
Thursday its announcement day today. What sparkly thing will SPL tinkle for us today?
SPL Price at posting:
90.0¢ Sentiment: None Disclosure: Held
(20min delay)